{"id":"NCT03961360","sponsor":"The University of Texas Health Science Center, Houston","briefTitle":"Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida","officialTitle":"Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida: An Open Label, Comparative Effectiveness, Randomized Controlled Trial (ASPREO Trial)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-05-06","primaryCompletion":"2023-04-10","completion":"2023-04-10","firstPosted":"2019-05-23","resultsPosted":"2024-05-08","lastUpdate":"2024-05-08"},"enrollment":220,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pre-Eclampsia","Hypertension in Pregnancy","Obesity"],"interventions":[{"type":"DRUG","name":"Aspirin 81 mg","otherNames":[]},{"type":"DRUG","name":"Aspirin 162 mg","otherNames":[]}],"arms":[{"label":"162 mg/day Aspirin","type":"EXPERIMENTAL"},{"label":"81 mg/day Aspirin","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the incidence of preeclampsia in obese pregnant women (BMI greater than 30) with a singleton gestation at less than 20 weeks and either a history of preeclampsia in a prior pregnancy or stage I hypertension or pre-gestational diabetes who are randomized to either 81mg/day aspirin or 162mg/day aspirin.","primaryOutcome":{"measure":"Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis","timeFrame":"3-7 months","effectByArm":[{"arm":"162 mg/Day Aspirin","deltaMin":37,"sd":null},{"arm":"81 mg/Day Aspirin","deltaMin":41,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":110},"commonTop":["Preeclampsia","Gestational hypertension","Necrotizing Enterocolitis"]}}